Clinical Trial Update: A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BAY2586116 for safety and efficacy in moderate to severe obstructive sleep apnea has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obstructive Sleep Apnea

Drugs mentioned

• BAY2586116

Snippet

Sponsor: Bayer | Conditions: Sleep Apnea, Obstructive | Phase 2 | Status: COMPLETED